Sethi_Lab

Dedicated physicians & scientists determined to improve outcomes in patients with gastrointestinal cancers through basic and translational research @DanaFarber

[Sethi_Lab @LabSethi]

A collaborative effort to engineer a dual knock-in reporter system to simultaneously broadcast aberrant stem cell and differentiation activity in colorectal cancer for discovery science. @JunQiLab @fonlikk @paulthekid_ @zxli_phd
https://t.co/8QiKWdNkBT

[Dana-Farber News @DanaFarberNews]

Zenocutuzumab offers a new targeted treatment option for patients with previously treated, advanced NRG1 fusion-positive cholangiocarcinoma. @DanaFarber's James Cleary, MD, PhD, discusses in @OncLearnNetwork the approval and the role of comprehensive molecular testing. https://t.co/IzBoNeYjuM

[Marlise R. Luskin MD, MSCE @LuskinMarlise]

Advanced fellowship in leukemia @DanaFarber
for 2027-2028, application is open. https://t.co/WuQ0HWm3Lj

[Muzumdar Lab @MuzumdarLab]

Please repost! We are seeking #PostDocs to join our lab in @YaleGenetics @YaleCancer @CancerYale to study #genetic and #host drivers of #PancreaticCancer and #LungCancer. Check out our newly updated website for more lab details! https://t.co/jyZnThDFwU

[Sethi_Lab @LabSethi]

A well-argued perspective on how developmental context influences cancer biology. It highlights why understanding the cell state in which transformation occurs can be as important as the mutations themselves.

[Elvin Wagenblast @Elvin_Wag]

🧬 Happy to share our new Perspective @NatureComms! Why can one mutation cause a childhood cancer in some cases and an adult cancer in others? The answer is developmental timing: early-life hits retain fetal programs, while later hits must rewire them. 🧵https://t.co/f525D1CiEM

[Dana-Farber News @DanaFarberNews]

FDA approval in cholangiocarcinoma: The FDA has approved zenocutuzumab for NRG1+ Cholangiocarcinoma. @DanaFarber's @JamesClearyMD helped lead research of the drug in this rare cancer type which has had limited treatment options.

➡️https://t.co/3BLxgAZZpi

[richard white @whitefishlab]

My department at Oxford is recruiting junior faculty to the Ludwig Institute for Cancer Research. A collaborative and stimulating department, with great access to the breadth of the Oxford environment. The positions come with core funding and cutting edge technologies. If interested, apply here: https://t.co/R5Lah3bZB3

[Dr. Anthony Letai @NCIDirector]

We asked early career scientists what they need: funding access, grant writing support, and mentorship. @theNCI listened.

We're launching a trans-institute training initiative to deliver exactly that. Learn more. https://t.co/oxEROWxxTo

[Thejus Jayakrishnan @ThejusJay]

#GI26 Our study underscores differing patient & physician perspectives on treatment trade-offs in 3L+ mCRC, particularly around #QOL and toxicity. Collaborative effort w/ @TakedaOncology #patientadvocate @cagirlinchi @colontown @Colorectalman @coloncanada @thermofisher

[Sethi_Lab @LabSethi]

We have already started using Cytotrace2. Great framework and tool when thinking about stem-like states and plasticity across cancers!

[Gunsagar Gulati @gungulati]

This is truly the perfect time to implement technology like this. We can accurately and swiftly annotate single cells based on their developmental potential with applications across biology and medicine. Excited to see this move ahead!

[Gunsagar Gulati @gungulati]

This is truly the perfect time to implement technology like this. We can accurately and swiftly annotate single cells based on their developmental potential with applications across biology and medicine. Excited to see this move ahead!

[Sethi_Lab @LabSethi]

Pornlada, Zhixin, and Paul led the way, thanks to their persistence and hard work. Thank @JamesClearyMD for the invaluable feedback, advice, and guidance throughout. Looking forward to the next set of therapeutics you help us find and investigate.

[Sethi_Lab @LabSethi]

Also excited to see the study in print. In addition to the findings, this work embodies complementary and generous science. Jun allowed us to screen his well-curated library of epigenetic degrades/inhibitors without batting an eye. We repaid him by asking him to do more…

[Jun Qi Lab @JunQiLab]

It is so exciting to see the final version of our collaborative work with @LabSethi. We found that blocking HDAC1/2 pushes CRC cells out of a stem-like state and into differentiation. We will work tother more to find novel therapeutic options for CRC. https://t.co/VGfazP6PeG

[Sethi_Lab @LabSethi]

Can we have a biotinylated and inactive version of the HDAC1/2 inhibitor? How do you do Chem-seq, Jun? In the end, we were able to follow our observations and publish these findings thanks to collaborative science fostered by @DanaFarber @DanaFarberNews

[Jun Qi Lab @JunQiLab]

It is so exciting to see the final version of our collaborative work with @LabSethi. We found that blocking HDAC1/2 pushes CRC cells out of a stem-like state and into differentiation. We will work tother more to find novel therapeutic options for CRC. https://t.co/VGfazP6PeG

[Oded Rechavi @OdedRechavi]

BIG ANNOUNCEMENT📣: I haven’t been this excited to be part of something new in 15 years… Thrilled to reveal the passion project I’ve been working on for the past year and a half!🙀🥳 It started from my frustration with the depressing effect that the current publishing system has on the well-being of myself, my team, and pretty much every scientist I know (maybe you’ve noticed from my stupid jokes… :) I was exhausted of dealing with the huge delays, reviewers that can be abusive, and how arbitrary it all is. Unfortunately, the most important factors are often WHO your reviewers are and who YOU are... It’s clear we need alternatives or at least ways to improve the situation. So, together with a really special and talented team we worked to develop this idea into “qed” a platform where you can get CONSTRUCTIVE feedback on your own work or CRITICALLY assess other people’s papers. It can be a real difference maker if many of you join us (thousands have tried it already, but today we release a NEW and much stronger version ;) Let’s harness qed to put the power back in the scientists’ hands, to do, to read & to publish science on our own terms. I’m dying for you to TRY IT, and it’s very simple - just drop a paper (the link to the website is in the replies👇) - it’s completely secure, private, and free, and you get results fast. Please show your support, SHARE, tell your friends, and let’s be the revolution 🫵!

[Srinivas Viswanathan @srviswanathan]

We’ve been busy 🐝s! Happy to share 5️⃣new preprints from the lab: one-liners below 👇#translocationRCC #CancerResearch @danafarber_GU [0/6]

[Sethi_Lab @LabSethi]

Congratulations to this year’s Nobel Laureates. As we celebrate their seminal discoveries, I hope we also take a moment to recognize the transformative contributions of Sasha Rudensky, an equally deserving scientist, the “fourth laureate”, if you will. #4thlaureate

[The Nobel Prize @NobelPrize]

BREAKING NEWS
The 2025 #NobelPrize in Physiology or Medicine has been awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi “for their discoveries concerning peripheral immune tolerance.”

[Sethi_Lab @LabSethi]

https://t.co/Nqhl4hAAYn

[DAVA Oncology @DAVAOnc]

Targeting CRC Plasticity! Dr. @Nilay_Sethi (@DanaFarber) shares work on endogenous reporter systems, revealing that HDAC1/2 inhibition promotes differentiation in colorectal cancer, thereby tackling therapy resistance. #DAVAGI #ColorectalCancer #GIOnc

[Sethi_Lab @LabSethi]

@DAVAOnc @Nilay_Sethi @DanaFarber Lively discussion of the latest and greatest!